Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.45 |
| ▸ | CTSB | P07858 | 6/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | F2 | P00734 | 5/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.40 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | MC1R | Q01726 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8163407 | 1.00 | CTSL (0.45) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8169709 | 0.96 | CTSL (0.43) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8169976 | 0.96 | CTSL (0.43) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8169986 | 0.96 | F2 (0.43) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8175162 | 0.96 | CTSL (0.44) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8164681 | 0.95 | CTSL (0.44) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8170857 | 0.94 | KLK1 (0.41) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8171330 | 0.93 | AGTR2 (0.40) | CTSLCTSBCTSSCTSKMC4R | |
| SCHEMBL8177623 | 0.93 | CTSL (0.43) | CTSLCTSBCTSSCTSKF2 | |
| SCHEMBL8171380 | 0.93 | CTSL (0.43) | CTSLCTSBCTSSCTSKF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293915-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| US-8293915-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| WO-2008097676-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | CTSL 36/4885CTSB 25/4885CTSS 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.